Archives
-
FAM50A and HCC: Evidence from a 2025 Study
2026-10-05
A 2025 study integrated multi-omic datasets, clinical modeling, tissue validation, and cell-based experiments to examine FAM genes in hepatocellular carcinoma. Its central finding was that elevated FAM50A expression tracks with aggressive disease and that FAM50A suppression reduces malignant cell behaviors in vitro, while important questions about causality and clinical utility remain.
-
L-Ornithine in Liver–Brain Axis Research
2026-10-04
L-Ornithine is a non-proteinogenic amino acid and urea cycle intermediate with relevance to ammonia detoxification and amino acid metabolism research. A 2025 Advanced Science study connected disrupted hepatic ornithine transcarbamylase activity with ornithine accumulation, astrocyte glycolytic impairment, and arsenic-associated neurological injury in experimental models. This overview separates those reported findings from broader interpretation, compares the evidence across model systems, and defines the study’s translational limitations.
-
Pregnenolone Carbonitrile: PXR and CNS Evidence
2026-10-03
Pregnenolone Carbonitrile, also called Pregnenolone-16α-carbonitrile or PCN, is best established as a rodent pregnane X receptor research agonist for studying xenobiotic-response pathways. A supplied 2025 mouse study expands the research context by reporting tissue-specific effects: PCN increased hepatic CYP3A11 and CYP2B10 but reduced these enzymes in the hippocampus, where protection from phenytoin-associated neuronal injury was linked to glucocorticoid receptor signaling rather than PXR. Claims involving liver fibrosis and hepatic stellate cell trans-differentiation remain provisional here because no primary antifibrotic study was supplied. Evidence is therefore strongest for mechanistic rodent research and weaker for therapeutic or human extrapolation.
-
Protease and Phosphatase Inhibitor Cocktail Workflow
2026-10-02
Protect lysates from proteolysis and dephosphorylation with an EDTA-free 100X formulation. This practical workflow connects cold extraction, phosphosite preservation, and HMGB1 post-translational modification analysis across mammalian cells, tissues, plants, yeast, and bacteria.
-
Pregnenolone Carbonitrile: Practical PXR Workflows
2026-10-01
Pregnenolone Carbonitrile enables controlled studies of rodent PXR signaling, cytochrome P450 CYP3A induction, and xenobiotic clearance. Its tissue-dependent behavior also makes it useful for comparing hepatic detoxification with hippocampal and antifibrotic responses, provided solvent, species, and mechanism are carefully controlled.
-
Omega-3 Protection from Cisplatin Nephrotoxicity
2026-10-01
The reference study shows that combined EPA and DHA reduce cisplatin-associated renal injury in mice and renal tubular epithelial cells more effectively than either fatty acid alone. Its mechanistic contribution is to connect p62–Keap1–Nrf2 antioxidant signaling with MDM2-mediated suppression of p53-dependent apoptosis, while also examining protection against chronic kidney fibrosis after repeated cisplatin exposure.
-
Osteoblast ECM1 Drives Anti-Androgen Resistance
2026-09-30
This study identifies osteoblast-derived ECM1 as a microenvironmental driver of enzalutamide resistance in bone metastatic prostate cancer. It connects ECM1 binding to cell-surface ENO1, ENO1 Y189 phosphorylation, GRB2/SOS1 recruitment, and MAPK activation, while showing that ECM1 or ENO1-directed intervention can restore treatment sensitivity.
-
IMP in RNA Modification Mapping by LC-MS
2026-09-30
IMP can serve as a chemically defined analytical reference within nucleotide and RNA workflows. This guide explains how to use IMP responsibly alongside spatial RNA-modification profiling, with assay decisions grounded in APEX-RNA-MS.
-
JNJ-26854165 (Serdemetan) Assay Guide
2026-09-29
Learn how to use JNJ-26854165 (Serdemetan) to separate growth arrest from true cell killing in p53-focused cancer research. The workflow combines HDM2 pathway readouts, orthogonal apoptosis measurements, and radiation-response testing for more interpretable results.
-
IRG1–Itaconic Acid Feedback Restrains TBK1
2026-09-29
A 2025 Cell Reports study identifies an immunometabolic feedback circuit in which IRG1-derived itaconic acid restrains excessive TBK1-dependent type I interferon production. The work maps this effect to alkylation of TBK1 at Cys605, impaired dimerization, and the development of itaconic acid derivatives ITA-5 and ITA-9 as candidate tools for studying IFN-I-driven hyperinflammation.
-
Firefly Luciferase mRNA as a Delivery Benchmark
2026-09-28
Firefly Luciferase mRNA can do more than report expression: it can reveal how efficiently an mRNA carrier reaches the cytosol and supports translation. This article connects Cap1 and 5-moUTP chemistry with delivery-system benchmarking inspired by calcium phosphate Pickering emulsions.
-
Imipenem: PBP Activity, Resistance, and Research Use
2026-09-28
Imipenem is a semisynthetic thienamycin antibiotic used in research on bacterial cell-wall inhibition and antibacterial activity. Its PBP-directed action should be interpreted alongside evidence that carbapenemase-encoding genes are associated with increased imipenem resistance in clinical Enterobacter cloacae isolates.
-
From Green Signal to mRNA Translation Strategy
2026-09-27
A fluorescent mRNA reporter can do more than mark successful delivery: used thoughtfully, it helps researchers separate RNA uptake, translation, cell stress, and assay performance. This article connects Cap 1 EGFP mRNA m1Ψ workflows to the broader challenge of optimizing mRNA expression, while clarifying what a reporter can—and cannot—predict about therapeutic candidates.
-
GnRH Antagonists with 2-OMe-5Pal at Position 3
2026-09-26
Samant and colleagues examined how replacing degarelix’s position-3 D-3Pal with racemic 3-(2-methoxy-5-pyridyl)-alanine affects GnRH receptor antagonism and duration of action. The D-configured analog retained strong in-vitro activity, whereas the L-configured analog was less potent; both were short-acting in the castrated-male-rat assay, showing that receptor potency alone did not predict prolonged action in vivo.
-
Vincristine Sulfate: Assay Workflows & Optimization
2026-09-25
Build more interpretable cancer research assays by connecting vincristine’s microtubule mechanism to dose selection, exposure timing, and orthogonal readouts. This workflow distinguishes product-backed benchmarks from experiment-specific starting conditions—and flags where a cited inflammation review should not be mistaken for evidence about vincristine.